Vascular endothelial growth factor gene polymorphism and protein expression in the pathogenesis of pterygium

Mei Ling Peng, Yi Yu Tsai, Jai Nien Tung, Chun Chi Chiang, Ying Cher Huang, Huei Lee, Ya Wen Cheng

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background and aims Vascular endothelial growth factor (VEGF) gene expression has been linked to cancer progression. Here we hypothesise that the polymorphism and protein expression of VEGF are correlated with the pathogenesis and therapy response of pterygium. Methods 60 pterygial and 121 normal conjunctival samples were collected to determine the genotypes and protein expression of VEGF. Primary pterygium cells (PECs) were used to confirm the effect of the VEGF polymorphism on the angiogenesis of pterygium. Results 48 (83.3%) pterygial specimens tested positive for VEGF protein expression, which was significantly higher than in the control groups (16.7%, pT variant, but not the ?2578C>A variant, was significantly higher in the pterygium group compared with the control group. VEGF protein expression was significantly higher in the 936 C/C group than in the 936 C/T and T/T groups (p=0.001). The results of our cell model showed that PECs with the C/C genotype had a higher angiogenesis ability and higher response to the antiangiogenesis drug bevacizumab than cells with the C/T and T/T genotypes. Conclusions We suggest that VEGF could be used as a target for pterygium therapy in patients with the 936C>T genotype.

Original languageEnglish
Pages (from-to)556-561
Number of pages6
JournalBritish Journal of Ophthalmology
Volume98
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Pterygium
Vascular Endothelial Growth Factor A
Genotype
Proteins
Control Groups
Gene Expression
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Vascular endothelial growth factor gene polymorphism and protein expression in the pathogenesis of pterygium. / Peng, Mei Ling; Tsai, Yi Yu; Tung, Jai Nien; Chiang, Chun Chi; Huang, Ying Cher; Lee, Huei; Cheng, Ya Wen.

In: British Journal of Ophthalmology, Vol. 98, No. 4, 2014, p. 556-561.

Research output: Contribution to journalArticle

Peng, Mei Ling ; Tsai, Yi Yu ; Tung, Jai Nien ; Chiang, Chun Chi ; Huang, Ying Cher ; Lee, Huei ; Cheng, Ya Wen. / Vascular endothelial growth factor gene polymorphism and protein expression in the pathogenesis of pterygium. In: British Journal of Ophthalmology. 2014 ; Vol. 98, No. 4. pp. 556-561.
@article{e84e1be93a3e4e5caa3adccacc534491,
title = "Vascular endothelial growth factor gene polymorphism and protein expression in the pathogenesis of pterygium",
abstract = "Background and aims Vascular endothelial growth factor (VEGF) gene expression has been linked to cancer progression. Here we hypothesise that the polymorphism and protein expression of VEGF are correlated with the pathogenesis and therapy response of pterygium. Methods 60 pterygial and 121 normal conjunctival samples were collected to determine the genotypes and protein expression of VEGF. Primary pterygium cells (PECs) were used to confirm the effect of the VEGF polymorphism on the angiogenesis of pterygium. Results 48 (83.3{\%}) pterygial specimens tested positive for VEGF protein expression, which was significantly higher than in the control groups (16.7{\%}, pT variant, but not the ?2578C>A variant, was significantly higher in the pterygium group compared with the control group. VEGF protein expression was significantly higher in the 936 C/C group than in the 936 C/T and T/T groups (p=0.001). The results of our cell model showed that PECs with the C/C genotype had a higher angiogenesis ability and higher response to the antiangiogenesis drug bevacizumab than cells with the C/T and T/T genotypes. Conclusions We suggest that VEGF could be used as a target for pterygium therapy in patients with the 936C>T genotype.",
author = "Peng, {Mei Ling} and Tsai, {Yi Yu} and Tung, {Jai Nien} and Chiang, {Chun Chi} and Huang, {Ying Cher} and Huei Lee and Cheng, {Ya Wen}",
year = "2014",
doi = "10.1136/bjophthalmol-2013-303436",
language = "English",
volume = "98",
pages = "556--561",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Vascular endothelial growth factor gene polymorphism and protein expression in the pathogenesis of pterygium

AU - Peng, Mei Ling

AU - Tsai, Yi Yu

AU - Tung, Jai Nien

AU - Chiang, Chun Chi

AU - Huang, Ying Cher

AU - Lee, Huei

AU - Cheng, Ya Wen

PY - 2014

Y1 - 2014

N2 - Background and aims Vascular endothelial growth factor (VEGF) gene expression has been linked to cancer progression. Here we hypothesise that the polymorphism and protein expression of VEGF are correlated with the pathogenesis and therapy response of pterygium. Methods 60 pterygial and 121 normal conjunctival samples were collected to determine the genotypes and protein expression of VEGF. Primary pterygium cells (PECs) were used to confirm the effect of the VEGF polymorphism on the angiogenesis of pterygium. Results 48 (83.3%) pterygial specimens tested positive for VEGF protein expression, which was significantly higher than in the control groups (16.7%, pT variant, but not the ?2578C>A variant, was significantly higher in the pterygium group compared with the control group. VEGF protein expression was significantly higher in the 936 C/C group than in the 936 C/T and T/T groups (p=0.001). The results of our cell model showed that PECs with the C/C genotype had a higher angiogenesis ability and higher response to the antiangiogenesis drug bevacizumab than cells with the C/T and T/T genotypes. Conclusions We suggest that VEGF could be used as a target for pterygium therapy in patients with the 936C>T genotype.

AB - Background and aims Vascular endothelial growth factor (VEGF) gene expression has been linked to cancer progression. Here we hypothesise that the polymorphism and protein expression of VEGF are correlated with the pathogenesis and therapy response of pterygium. Methods 60 pterygial and 121 normal conjunctival samples were collected to determine the genotypes and protein expression of VEGF. Primary pterygium cells (PECs) were used to confirm the effect of the VEGF polymorphism on the angiogenesis of pterygium. Results 48 (83.3%) pterygial specimens tested positive for VEGF protein expression, which was significantly higher than in the control groups (16.7%, pT variant, but not the ?2578C>A variant, was significantly higher in the pterygium group compared with the control group. VEGF protein expression was significantly higher in the 936 C/C group than in the 936 C/T and T/T groups (p=0.001). The results of our cell model showed that PECs with the C/C genotype had a higher angiogenesis ability and higher response to the antiangiogenesis drug bevacizumab than cells with the C/T and T/T genotypes. Conclusions We suggest that VEGF could be used as a target for pterygium therapy in patients with the 936C>T genotype.

UR - http://www.scopus.com/inward/record.url?scp=84896544451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896544451&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2013-303436

DO - 10.1136/bjophthalmol-2013-303436

M3 - Article

VL - 98

SP - 556

EP - 561

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 4

ER -